Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$973.80 USD

973.80
351,356

+5.80 (0.60%)

Updated May 10, 2024 04:00 PM ET

After-Market: $972.97 -0.83 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 461 - 480 ( 591 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 461

09/03/2014

Company Report

Pages: 8

Alirocumab''s Successful ODYSSEY Continues; Target Upped to $422

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 462

08/26/2014

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 463

08/11/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 464

08/11/2014

Company Report

Pages: 4

Eylea Keeps Gaining Ground; Receives E.U. DME Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 465

08/05/2014

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 466

08/05/2014

Company Report

Pages: 7

2Q14 Results, Eylea Growth & Advanced Antibody Pipeline

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 467

07/31/2014

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 468

07/31/2014

Daily Note

Pages: 5

Priority Review Voucher Purchased for Alirocumab; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 469

07/30/2014

Company Report

Pages: 4

That''s A Lot of Positive Phase III''s; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 470

07/30/2014

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 471

07/30/2014

Company Report

Pages: 6

Another Win for Eylea; Approved for DME in the U.S.; Target Upped to $399

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 472

07/18/2014

Daily Note

Pages: 3

MIDDAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 473

07/18/2014

Company Report

Pages: 4

Eylea Sustains Vision Improvement in DME for 2 Years; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 474

07/10/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 475

07/10/2014

Company Report

Pages: 7

Positive Phase IIb Data In Atopic Dermatitis Bolsters Dupilumab Position

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 476

07/01/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 477

06/25/2014

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 478

06/13/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 479

06/12/2014

Company Report

Pages: 7

Sarilumab Continues to Impress & Clears Way Ahead; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 480

06/12/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party